| Dr Daniel Marelli, MD | |
|
540 S Governors Ave Ste 101a, Dover, DE 19904-3530 | |
| (302) 744-7980 | |
| (302) 744-7989 |
| Full Name | Dr Daniel Marelli |
|---|---|
| Gender | Male |
| Speciality | Cardiac Surgery |
| Experience | 38 Years |
| Location | 540 S Governors Ave Ste 101a, Dover, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518983147 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | C1-0008629 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayhealth Hospital, Kent Campus | Dover, DE | Hospital |
| Bayhealth Hospital, Sussex Campus | Milford, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bayhealth Medical Center, Inc | 1658364740 | 288 |
News Archive
Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
Mitochondrial diseases are a diverse group of disorders caused by mutated genes that impair energy production in a patient's cells, often with severe effects.
University of Southampton researchers are at the forefront of research into mechanobiology, an emerging field of science combining biology and engineering, which investigates the influence of mechanical forces on cellular and molecular processes.
A unique new medicine that can start and hasten healing of diabetic and other chronic sores is being developed at Umeå University in Sweden. After several years of successful experimental research, it is now ready for clinical testing.
› Verified 5 days ago
| Entity Name | Bayhealth Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467546135 PECOS PAC ID: 1658364740 Enrollment ID: O20040405001600 |
News Archive
Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
Mitochondrial diseases are a diverse group of disorders caused by mutated genes that impair energy production in a patient's cells, often with severe effects.
University of Southampton researchers are at the forefront of research into mechanobiology, an emerging field of science combining biology and engineering, which investigates the influence of mechanical forces on cellular and molecular processes.
A unique new medicine that can start and hasten healing of diabetic and other chronic sores is being developed at Umeå University in Sweden. After several years of successful experimental research, it is now ready for clinical testing.
› Verified 5 days ago
| Entity Name | Bayhealth Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1023006434 PECOS PAC ID: 1658364740 Enrollment ID: O20160527000094 |
News Archive
Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
Mitochondrial diseases are a diverse group of disorders caused by mutated genes that impair energy production in a patient's cells, often with severe effects.
University of Southampton researchers are at the forefront of research into mechanobiology, an emerging field of science combining biology and engineering, which investigates the influence of mechanical forces on cellular and molecular processes.
A unique new medicine that can start and hasten healing of diabetic and other chronic sores is being developed at Umeå University in Sweden. After several years of successful experimental research, it is now ready for clinical testing.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Marelli, MD 640 S. State Street, Mail Code 3055, Dover, DE 19901-3530 Ph: (302) 480-1688 | Dr Daniel Marelli, MD 540 S Governors Ave Ste 101a, Dover, DE 19904-3530 Ph: (302) 744-7980 |
News Archive
Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies.
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker.
Mitochondrial diseases are a diverse group of disorders caused by mutated genes that impair energy production in a patient's cells, often with severe effects.
University of Southampton researchers are at the forefront of research into mechanobiology, an emerging field of science combining biology and engineering, which investigates the influence of mechanical forces on cellular and molecular processes.
A unique new medicine that can start and hasten healing of diabetic and other chronic sores is being developed at Umeå University in Sweden. After several years of successful experimental research, it is now ready for clinical testing.
› Verified 5 days ago
Gary Walter Szydlowski, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 540 S Governors Ave Ste 101a, Dover, DE 19904 Phone: 302-744-7980 Fax: 302-744-7989 | |
Paul A Fedalen, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 540 S Governors Ave Ste 101a, Dover, DE 19904 Phone: 302-744-7980 Fax: 302-744-7989 | |
John Dana Mannion, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 540 S Governors Ave, Suite 101a, Dover, DE 19904 Phone: 302-744-7980 |